Comprensione delle relazioni tra MRD e terapia con cellule T CAR
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
Terapia con cellule staminali mesenchimali nei disturbi neurologici
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven't always worked, which has led to a change toward new methods like cell-based therapies. Beca..
La designazione di farmaco orfano è stata assegnata dalla FDA alla CART T-Cell Therapy A2B530 per il trattamento del cancro del colon-retto
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
Amtagvi di Iovance è approvato dalla USFDA come prima terapia con cellule T per un tumore solido
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used directly on solid tumors.The drug..
Amivantamab-vmjw è approvato dalla USFDA per le indicazioni sul cancro polmonare non a piccole cellule con esone 20 dell'EGFR mutato per inserzione
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor receptor (EGFR) exon 20 insertio..
Osimertinib con chemioterapia è approvato dalla USFDA per il carcinoma polmonare non a piccole cellule con mutazione EGFR
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (la/mNSC..
Lifileucel è approvato dalla USFDA per il melanoma non resecabile o metastatico
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for adult patients with unresectable or metastatic melanoma who have been..
Tepotinib è approvato dalla USFDA per il carcinoma polmonare metastatico non a piccole cellule
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenchymal-epithelial transition (M..
Il liposoma di irinotecan è approvato dalla USFDA per il trattamento di prima linea dell'adenocarcinoma pancreatico metastatico
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on February 13, 2024, for treating metastatic pancreatic adenocarcinoma as the..
Erdafitinib è approvato dalla USFDA per il carcinoma uroteliale localmente avanzato o metastatico
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic urothelial carcinoma (mUC). Patie..